Treating drug-resistant irritable bowel syndrome with hypnosis: A case report

2019 ◽  
Vol 2 (1) ◽  
pp. 20-23
Author(s):  
Amrah Abdullayev ◽  
Zaur Orudjev
Keyword(s):  
Irritable Bowel Syndrome ◽  
Case Report ◽  
Evidence Base ◽  
Bowel Habit ◽  
Drug Resistant ◽  
Functional Disorder ◽  
Pharmacological Treatments ◽  
Limited Effect ◽  
Irritable Bowel ◽  
High Comorbidity

 Irritable Bowel Syndrome (IBS) is a functional disorder of gastrointestinal system, characterized by abdominal pain, bowel habit change, bloating and etc. Pharmacological treatments usually have limited effect on IBS. IBShas high comorbidity with mood and anxiety disorders which are seems related to bowel symptoms . Treatment choices for managing IBS are pharmacological, dietary, lifestyle change, physical activity and psychotherapy. Effectiveness of psychotherapeutic procedures for IBS was demonstrated before. In this case report, patient with resistant IBS,  gone under hypnotherapy and this trial serves as little contribution to the evidence base for the treatment of IBS by applying psychological approach.

scholarly journals Irritable bowel syndrome: Is it “irritable brain” or “irritable bowel”?

2015 ◽  
Vol 06 (04) ◽  
pp. 568-577 ◽  
Author(s):  
Susanta Kumar Padhy ◽  
Swapnajeet Sahoo ◽  
Sonali Mahajan ◽  
Saroj Kumar Sinha
Keyword(s):  
Irritable Bowel Syndrome ◽  
Functional Gastrointestinal Disorders ◽  
Evidence Base ◽  
North India ◽  
Bowel Habit ◽  
Western World ◽  
Pharmaceutical Industries ◽  
Underlying Mechanisms ◽  
Irritable Bowel ◽  
Care Costs

ABSTRACTIrritable bowel syndrome (IBS) has been recognized as one of the most common and best studied disorders among the group of functional gastrointestinal disorders. It is a functional bowel disorder in which abdominal pain or discomfort is associated with defecation or a change in bowel habit. In the Western world, IBS appears to affect up to 20% of the population at any given time but in Asian countries, the median value of IBS prevalence defined by various criteria ranges between 6.5% and 10.1%, and community prevalence of 4% is found in North India. Those attending gastroenterology clinics represent only the tip of the iceberg. The disorder substantially impairs the quality of life, and the overall health-care costs are high. IBS has therefore gained increased attention from clinicians, researchers, and pharmaceutical industries. It is often frustrating to both patients and physicians as the disease is usually chronic in nature and difficult to treat. However, the understanding of IBS has been changing from time to time and still most of its concepts are unknown. In this review we have discussed, debated, and synthesized the evidence base, focusing on underlying mechanisms in the brain and bowel. We conclude that it is both brain and bowel mechanisms that are responsible. The clinical implication of such mechanisms is discussed.

scholarly journals AYURVEDIC MANAGEMENT OF GRAHANI ROGA- CASE REPORT

2021 ◽  
Vol 9 (11) ◽  
pp. 2890-2892
Author(s):  
Aparna. T. P ◽  
Archana. S. Dachewar
Keyword(s):  
Irritable Bowel Syndrome ◽  
Case Report ◽  
Bowel Habit ◽  
Altered Bowel Habit ◽  
Irritable Bowel

Grahani Roga is a disease of Annavaha Srotas caused due to the formation of Ama due to Mandagni. Elimination of Vidagadha or Apakva anna through the Guda is known as Grahani Roga. Acharya Charaka has mentioned that the improperly digested food due to Mandagni when moved either in Urdhwa or Adho-Marga leads to Grahani Roga. Acharya Sushruta and Madhavakara have mentioned that patients of Atisara, during the stage of Agnimandya, if taken virudhha ahara, may lead to Grahani Roga. Muhur Baddha Muhur drava mala pravritti (altered bowel habit), Shleshma mala pravritti (mucous in stool) are the main symptoms of this disease. The symptoms of Grahani resemble most irritable bowel syndrome (IBS) symptoms. So, we can correlate the Grahani roga with IBS. A diagnosed case of Grahani (IBS) is discussed here who was treated with Bilwavaleha, Sanjeevani Churna, Arogyavardhini vati, Brahmi vati, Manasamitravatakam and Hingwashtak churna. Keywords: Grahani roga, IBS, Agnimandya, Case report

scholarly journals (Poly)phenols in Inflammatory Bowel Disease and Irritable Bowel Syndrome: A Review

Molecules ◽  
2021 ◽  
Vol 26 (7) ◽  
pp. 1843
Author(s):  
Marilyn Hagan ◽  
Bu' Hussain Hayee ◽  
Ana Rodriguez-Mateos
Keyword(s):  
Inflammatory Bowel Disease ◽  
Irritable Bowel Syndrome ◽  
Bowel Disease ◽  
Evidence Base ◽  
Therapeutic Benefit ◽  
Markers Of Inflammation ◽  
Related Quality ◽  
Health Related ◽  
Inflammatory Bowel ◽  
Irritable Bowel

(Poly)phenols (PPs) may have a therapeutic benefit in gastrointestinal (GI) disorders, such as irritable bowel syndrome (IBS) or inflammatory bowel disease (IBD). The aim of this review is to summarise the evidence-base in this regard. Observational evidence does not give a clear indication that PP intake has a preventative role for IBD or IBS, while interventional studies suggest these compounds may confer symptomatic and health-related quality of life improvements in known patients. There are inconsistent results for effects on markers of inflammation, but there are promising reports of endoscopic improvement. Work on the effects of PPs on intestinal permeability and oxidative stress is limited and therefore conclusions cannot be formed. Future work on the use of PPs in IBD and IBS will strengthen the understanding of clinical and mechanistic effects.

Irritable bowel syndrome

2020 ◽  
pp. 2951-2959
Author(s):  
Adam D. Farmer ◽  
Qasim Aziz
Keyword(s):  
Irritable Bowel Syndrome ◽  
Abdominal Pain ◽  
Recurrent Abdominal Pain ◽  
Bowel Habit ◽  
Western World ◽  
Older Individuals ◽  
Butyl Bromide ◽  
Rome Iii ◽  
Fermentable Carbohydrates ◽  
Irritable Bowel

Symptoms suggestive of disturbed lower gastrointestinal function without adequate explanation are very common in adults in the Western world, up to 15% of whom experience such symptoms at any one time, although most do not seek medical advice. The currently used terms are best viewed as an attempt to provide some clinically useful, rather than pathophysiologically accurate, categorization of patients and their symptoms based on disordered gut–brain interactions. Irritable bowel syndrome is defined according to the Rome III criteria as recurrent abdominal pain or discomfort associated with a change in bowel habit for at least 6 months, with symptoms experienced on at least 3 days of at least 3 months. Many subtypes are recognized. Routine haematological and biochemical screening is usually performed on the assumption that it will be normal. Features that raise the suspicion of organic disease and indicate a need for further investigation include the onset of symptoms in middle-aged or older individuals, weight loss, or blood in the stool. Management remains empirical: no single pharmacological agent or group of agents has ever been found to be consistently effective. The principal task of the physician is to provide explanation and reassurance (sometimes supplemented by psychological treatments), but particular symptoms are often treated as follows: (1) constipation—defecation may be eased by supplementary dietary fibre and poorly absorbed fermentable carbohydrates which increase faecal bulk and soften the stool; osmotic laxatives and enemas are used for the severely constipated patient, as well as more novel agents; (2) diarrhoea—attention to diet is often helpful, as are simple antidiarrhoeal agents; and (3) abdominal pain—antispasmodics (e.g. hyoscine butyl bromide) are frequently used, as are antidepressants.

scholarly journals Non-pharmacological treatments for irritable bowel syndrome: study protocol of an umbrella review of systematic review and meta-analyses

BMJ Open ◽  
2019 ◽  
Vol 9 (3) ◽  
pp. e027778 ◽  
Author(s):  
Song Jin ◽  
Yi-Fan Li ◽  
Di Qin ◽  
Dan-Qing Luo ◽  
Hong Guo ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Meta Analysis ◽  
Small Study ◽  
Cochrane Central Register ◽  
Pharmacological Treatments ◽  
Umbrella Review ◽  
Study Heterogeneity ◽  
Ethical Approval ◽  
Irritable Bowel ◽  
Meta Analyses

IntroductionNon-pharmacological treatments are used in the management of irritable bowel syndrome, and their effectiveness has been evaluated in multiple meta-analyses. The robustness of the results in the meta-analyses was not evaluated. We aimed to assess whether there is evidence of diverse biases in the meta-analyses and to identify the treatments without evidence of risk of bias.Methods and analysisWe will search MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, Web of Science and CINAHL Plus for meta-analyses that evaluate the effectiveness of non-pharmacological treatments. The time of publication will be limited from inception to December 2018. The credibility of the meta-analyses will be evaluated by assessing between-study heterogeneity, small-study effect and excess significance bias. The between-study heterogeneity will be assessed using the Cochrane’s Q test, and the extent of the heterogeneity will be classified using the I2statistics. The existence of a small-study effect in a meta-analysis will be evaluated using the funnel plot method and confirmed by Egger’s test. Excess significance bias will be evaluated by comparing the expected number of clinical studies with positive findings with the observed number.Ethics and disseminationNo formal ethical approval is required since we will use publicly available data. We will disseminate the findings of the umbrella review through publication in a peer-reviewed journal and conference presentations.PROSPERO registration numberCRD42018111516.

scholarly journals Efficacy of psychological therapies for irritable bowel syndrome: systematic review and network meta-analysis

Gut ◽  
2020 ◽  
Vol 69 (8) ◽  
pp. 1441-1451 ◽  
Author(s):  
Christopher J Black ◽  
Elyse R Thakur ◽  
Lesley A Houghton ◽  
Eamonn M M Quigley ◽  
Paul Moayyedi ◽  
...  
Keyword(s):  
Systematic Review ◽  
Irritable Bowel Syndrome ◽  
Meta Analysis ◽  
Contingency Management ◽  
Evidence Base ◽  
Routine Care ◽  
National Guidelines ◽  
Psychological Therapies ◽  
Registration Number ◽  
Irritable Bowel

ObjectivesNational guidelines for the management of irritable bowel syndrome (IBS) recommend that psychological therapies should be considered, but their relative efficacy is unknown, because there have been few head-to-head trials. We performed a systematic review and network meta-analysis to try to resolve this uncertainty.DesignWe searched the medical literature through January 2020 for randomised controlled trials (RCTs) assessing efficacy of psychological therapies for adults with IBS, compared with each other, or a control intervention. Trials reported a dichotomous assessment of symptom status after completion of therapy. We pooled data using a random effects model. Efficacy was reported as a pooled relative risk (RR) of remaining symptomatic, with a 95% CI to summarise efficacy of each comparison tested, and ranked by therapy according to P score.ResultsWe identified 41 eligible RCTs, containing 4072 participants. After completion of therapy, the psychological interventions with the largest numbers of trials, and patients recruited, demonstrating efficacy included self-administered or minimal contact cognitive behavioural therapy (CBT) (RR 0.61; 95% CI 0.45 to 0.83, P score 0.66), face-to-face CBT (RR 0.62; 95% CI 0.48 to 0.80, P score 0.65) and gut-directed hypnotherapy (RR 0.67; 95% CI 0.49 to 0.91, P score 0.57). After completion of therapy, among trials recruiting only patients with refractory symptoms, group CBT and gut-directed hypnotherapy were more efficacious than either education and/or support or routine care, and CBT via the telephone, contingency management, CBT via the internet and dynamic psychotherapy were all superior to routine care. Risk of bias of trials was high, with evidence of funnel plot asymmetry; the efficacy of psychological therapies is therefore likely to have been overestimated.ConclusionsSeveral psychological therapies are efficacious for IBS, although none were superior to another. CBT-based interventions and gut-directed hypnotherapy had the largest evidence base and were the most efficacious long term.Trial registration numberThe study protocol was published on the PROSPERO international prospective register of systematic reviews (registration number CRD 42020163246).

Some antispasmodic drugs for the irritable bowel syndrome

1986 ◽  
Vol 24 (24) ◽  
pp. 93-95
Keyword(s):  
Irritable Bowel Syndrome ◽  
Abdominal Pain ◽  
Intestinal Disease ◽  
Bowel Habit ◽  
Dietary Advice ◽  
Irritable Bowel

Irritable bowel syndrome (IBS) is commonly diagnosed when the typical symptoms of irregular bowel habit, abdominal pain and distension, and a feeling of incomplete defaecation are not associated with other gastro-intestinal disease. The management of the patient with IBS has been covered previously1 but if dietary advice, reassurance and simple psychotherapy have proved unhelpful the doctor may be under pressure to prescribe as symptoms are usually recurrent. We now review the evidence to support the use of some antispasmodic drugs.

Sign in / Sign up

Export Citation Format

Share Document